LUNG ADENOCARCINOMA
Clinical trials for LUNG ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LUNG ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for LUNG ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Blood tests may help decide best time to switch lung cancer drugs
Disease control CompletedThis phase 2 trial tested two drugs, osimertinib and gefitinib, in 156 people with advanced EGFR-mutant lung cancer. The goal was to see if using blood tests (liquid biopsies) to detect genetic changes could help decide when to switch treatments, compared to standard scans. The s…
Matched conditions: LUNG ADENOCARCINOMA
Phase: PHASE2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a diabetes drug boost lung cancer treatment?
Disease control CompletedThis study looked at whether adding metformin (a common diabetes medicine) to standard chemotherapy and radiation helps people with stage III non-small cell lung cancer live longer without their cancer getting worse. About 170 adults with advanced lung cancer took part. The goal …
Matched conditions: LUNG ADENOCARCINOMA
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug RC88 shows promise in early trial for hard-to-treat cancers
Disease control CompletedThis study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors or slow their growth. The study was completed and looked at sid…
Matched conditions: LUNG ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Old arthritis drug paired with immune suppressant shows promise against tough lung cancers
Disease control CompletedThis study tested two drugs—auranofin (originally for arthritis) and sirolimus (an immune suppressant)—in 29 people with advanced or recurrent lung cancer who had no standard options left. The goal was to find the safest dose and see if the combination could slow cancer growth. T…
Matched conditions: LUNG ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 26, 2026 13:58 UTC